BIOLASE, Inc.
BIOLASE, Inc. (BIOL) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
biol · stock forecast · 6 analysts (3M) · FMP · updated Nov 6, 2025
Analyst Rating & Consensus
Based on 6 Wall Street analysts in the past 3 months
Buy
6 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$0.00
Consensus
$0.00
+0.0% upside
Low
$0.00
Median: $0 · Last Close: $0.01
Short-Term Price Prediction
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
NEUTRAL
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · BIOL · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2024-08-12 | Benchmark | Maintains | Speculative Buy→Speculative Buy |
| 2024-05-14 | Benchmark | Maintains | Speculative Buy→Speculative Buy |
| 2024-04-01 | Ascendiant Capital | Maintains | Buy→Buy |
| 2024-03-22 | Benchmark | Maintains | Speculative Buy→Speculative Buy |
| 2023-05-31 | Lake Street | Maintains | Buy→Buy |
| 2023-03-29 | Maxim Group | Maintains | Buy→Buy |
| 2014-05-13 | Wallachbeth | Downgrade ↓ | Buy→Hold |
| 2013-09-12 | Sidoti & Co. | Upgrade ↑ | Neutral→Buy |
| 2013-07-03 | Ascendiant Capital | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on BIOLASE, Inc. (BIOL) stock. Of the recent 9 rating actions, 1 were upgrades and 1 were downgrades. 6 analysts currently cover BIOL.
Analyst Recommendation Trends
BIOL analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$39M
↓ 16.0% YoY
Revenue Next Year
$48M
↑ 24.6% YoY
EPS This Year
$-256.25
EPS Next Year
$-345.33
↑ 34.8% YoY
EPS ForecastReported vs Estimated
Analysts forecast BIOL EPS of $-256.25 for the current fiscal year, based on estimates from 1 analysts. The BIOL revenue forecast is $39M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The BIOL stock forecast is supported by two independent data sources: analyst consensus ratings from 6 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus BIOL price target is $0.00 (+0.0% upside), with an analyst consensus of Buy.
BIOLASE, Inc. trades on NASDAQ under the ticker BIOL. The BIOL stock outlook for 2027 is broadly positive, supported by a Buy consensus among 83% of covering analysts.
Frequently asked questions
BIOL forecast · 8 questionsAccording to 6 Wall Street analysts, the average 12-month BIOL price target is $0.00, with a high forecast of $0.00 and a low of $0.00. The median price target is shown in the chart above when available. This implies +0.0% potential upside from the current price of $0.01.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.